US · Healthcare · Diagnostics & Research
EPS came in at -0.01 against a street estimate of -0.06 — a beat of 83.3%.
Analysts rate NeoGenomics Inc a buy (8 buy, 4 hold, 0 sell out of 12) with an average price target of $19.72.
CONFIDENT NeoGenomics beat Q2 revenue expectations with 11% YoY growth; raised FY26 guidance. NGS grew 26%, clinical up 14%. Margins expanded 260bps. Pharma segment weak but viewed as non-core. Q2 FY26 Northeast NGS pull-through accelerating alongside higher-value testing adoption. Analysts pressed sustainability of AUP growth amid competition (management cited durable RCM and mix-shift runway), pharma business importance (framed as pipeline enabler, not core growth driver), and targeted-to-CGP transition headroom (several years of runway cited). Management deflected on specific share-win percentages and 2027 guidance, deferring to next quarter update. 2026-07-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.53% |
| First Light Asset Management, LLC | 9.56% |
| First Trust Advisors L.P. | 7.87% |
| Greenhouse Funds LLLP | 6.67% |
| Vanguard Portfolio Management, LLC | 5.93% |
| Vanguard Capital Management, LLC | 4.40% |
| BRAIDWELL LP | 4.37% |
| State Street Corp | 3.99% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 NEOGENOMICS, INC. - FORM 8-K SUMMARY OTHER NOTABLE POINTS • Executive Departure: Alicia Olivo, EVP of General Counsel & Business Development, is tra | 2026-08-11 |
| Quarterly report · Q2 2026 NEOGENOMICS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $201.7 million (up 11% vs. Q2 2025: $181.3 million) • Six-Month 2026 Re | 2026-07-28 |
| Results announced · Q3 2026 NEOGENOMICS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue Q2 2026: $202 million, up 11% year-over-year from $181 million in Q2 2025 • Cl | 2026-07-28 |
| Reg FD disclosure · Q3 2026 NEOGENOMICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Settlement payment: $9,813,260 to U.S. Department of Justice • Prior reserve accrual (as of | 2026-07-20 |
| Board / officer change · Q2 2026 NEOGENOMICS, INC. — FORM 8-K SUMMARY OTHER NOTABLE POINTS • Board Expansion: Board of Directors increased from 9 to 10 members on June 23, 2026 • N | 2026-06-25 |
| Quarterly report · Q1 2026 NEOGENOMICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net revenue: $186.7 million (Q1 2026) vs. $168.0 million (Q1 2025) – up 11.1% • Net loss | 2026-04-28 |
| Proxy statement · Q4 2025 NEOGENOMICS, INC. PROXY STATEMENT SUMMARY CEO TOTAL COMPENSATION • CEO compensation figures not explicitly stated in provided document excerpt. Full | 2026-04-06 |
| Annual report FY2025 NEOGENOMICS, INC. (NEO) – 2025 FORM 10-K SUMMARY HEADLINE NUMBERS • Market capitalization: $680.2 million as of June 30, 2025 (based on $7.31 share | 2026-02-17 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for NeoGenomics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.